Abstract
BackgroundEndometrial cancer (EC) is one of the most common female malignant tumors. The immunity is believed to be associated with EC patients’ survival, and growing studies have shown that aberrant alternative splicing (AS) might contribute to the progression of cancers.MethodsWe downloaded the clinical information and mRNA expression profiles of 542 tumor tissues and 23 normal tissues from The Cancer Genome Atlas (TCGA) database. ESTIMATE algorithm was carried out on each EC sample, and the OS-related different expressed AS (DEAS) events were identified by comparing the high and low stromal/immune scores groups. Next, we constructed a risk score model to predict the prognosis of EC patients. Finally, we used unsupervised cluster analysis to compare the relationship between prognosis and tumor immune microenvironment.ResultsThe prognostic risk score model was constructed based on 16 OS-related DEAS events finally identified, and then we found that compared with high-risk group the OS in the low-risk group was notably better. Furthermore, according to the results of unsupervised cluster analysis, we found that the better the prognosis, the higher the patient’s ESTIMATE score and the higher the infiltration of immune cells.ConclusionsWe used bioinformatics to construct a gene signature to predict the prognosis of patients with EC. The gene signature was combined with tumor microenvironment (TME) and AS events, which allowed a deeper understanding of the immune status of EC patients, and also provided new insights for clinical patients with EC.
Highlights
Endometrial cancer (EC) is one of the most common malignances in females [1], and it often occurs in perimenopausal and postmenopausal women
We obtained the mRNA expression profile of 542 patients with EC from The Cancer Genome Atlas (TCGA) database, and the stromal/immune scores of these patients were obtained by estimate algorithm (Supplementary Table 2)
The K-M curves showed that low immune scores were notably related to poorer survival of patients with EC (Figure 2A), there was no significant correlation between stromal scores and prognosis of patients with EC (Figure 2B)
Summary
Endometrial cancer (EC) is one of the most common malignances in females [1], and it often occurs in perimenopausal and postmenopausal women. For earlystage EC patients, the treatments are effective, the risk of recurrence is low, and the prognosis is good. For advanced stage EC patients, these treatment options are limited in efficacy and prone to relapse, with a 5-year survival rate of only 10-30% [3, 4]. There are no very effective biomarkers to predict the prognosis of patients with EC. Endometrial cancer (EC) is one of the most common female malignant tumors. The immunity is believed to be associated with EC patients’ survival, and growing studies have shown that aberrant alternative splicing (AS) might contribute to the progression of cancers
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
